After 2 (long) years, the widely-popular ISPE Mid-Atlantic Science & Technology (MAST) Showcase was back in person, with excitement and energy filling the rooms as professionals from across the BioHealth Capital Region and beyond gathered at the Turf Valley Resort in Ellicott City, MD.
Today, we are excited to announce the winners of our 2nd Annual BioBuzz Awards. The BioBuzz Awards are a celebration of the exciting and groundbreaking work being done by the BioHealth Capital Region (BHCR) life science community and the individuals that make innovation happen across Maryland, Virginia, and Washington, D.C.
The Horizon report is based on survey responses from more than 500 industry leaders who provide insight into all corners of the industry. The investigation of cell and gene therapies is proving to be a disruptive space that is reshaping biopharma business models. When cell therapies first went into human testing, Walters said the big question on the minds of the scientists was, “will it work?”
We’re excited to announce this year’s finalists for the second annual 2021 BioBuzz Awards. These awards celebrate the people and companies across our regional community and their efforts and accomplishments to impact human health and build a stronger biotech community.
The Amicus facility encompasses 75,000 square feet of the top three floors of a new building located on Market Street in Philadelphia. The space includes office space, as well as state-of-the-art laboratories. It’s expected to provide space for approximately 200 researchers and drug developers focused exclusively on gene therapies.
CRB, a global architecture, engineering, construction (AEC) and consulting firm, with a major office in Rockville, Maryland, has been on the cutting edge of the biotechnology real estate business for over 35 years. Established in 2014 with just 8 people, over the past 2 years CRB’s Rockville office has grown from 50 employees to over 90, says Ben Skowronski, office lead. And they are still growing!
The Plymouth Group, which owns the property, has partnered with Centerbridge Partners, L.P. to turn the former Budd Plant in Philadelphia into a facility that will support biomanufacturing efforts of companies across Cellicon Valley. The new site will position Philadelphia as a key lynchpin in biomanufacturing and continue the city’s growth as one of the top biopharma hubs in the United States.
Philadelphia’s soaring life sciences commercial real estate market is being driven by the combination of strong demand for advanced lab and manufacturing facilities and near record low vacancy rates.
The ongoing pandemic response by the biopharma industry has been historic. Biotech companies and contract development and manufacturing organizations, along with the entire supply chain, have worked together to develop several SARS-CoV-2 vaccines, achieved Emergency Use Authorization(EUA) from the FDA, and began delivering desperately needed protection into people’s arms in less than a calendar year.
In 2020 we introduced a new series titled “5 Questions With…” in an effort to spotlight individuals from across the BioHealth Capital Region and beyond. Providing this platform has allowed us to help share the stories of industry peers and show that there isn’t a single “right” way to becoming an industry success.